Hutchinson S J, Goldberg D J, King M, Cameron S O, Shaw L E, Brown A, MacKenzie J, Wilson K, MacDonald L
Scottish Centre for Infection and Environmental Health, and Public Health and Health Policy Section, University of Glasgow, Glasgow, UK.
Gut. 2004 Apr;53(4):593-8. doi: 10.1136/gut.2003.027383.
(A) To examine the prevalence and demographic characteristics of hepatitis C virus (HCV) infection among childbearing women in Scotland; and (B) to determine the extent of maternal HCV infection diagnosed prior to birth.
(A) Residual dried blood spot samples from routine neonatal screening, collected throughout Scotland during March-October 2000, were unlinked from identifiers and tested anonymously for HCV antibodies; and (B) electronic record linkage of Scotland's databases of births and diagnosed HCV infections was performed.
(A) Of 30,259 samples, 121 were enzyme linked immunosorbent assay repeat reactive and 88 of these were confirmed as anti-HCV positive in the recombinant immunoblot assay, representing a seroprevalence of 0.29-0.40%. HCV seroprevalence was high among 25-29 year olds (0.4-0.57%), in high deprivation areas (0.92-1.07%), and in Greater Glasgow (0.83-0.96%) and Grampian (0.38-0.62%). Adjusted relative risk for HCV infection was highest among residents in high deprivation areas of Glasgow (7.2 (95% confidence interval 2.0-25.5)). (B) Of 121 HCV infections found among women at delivery, 24% and 46% were estimated to have been diagnosed prior to pregnancy and birth, respectively.
HCV prevalence among Scottish childbearing women is consistent with that expected from injecting drug use. Based on reported rates of mother to child transmission, 8-11 paediatric infections are expected per annum. Diagnosis in only 24% of infected women prior to pregnancy indicates the extent to which HCV goes unrecognised in the injecting community. The current HCV screening approach-to test only those with a history of injecting drug use (or other risk factors for infection)-identifies approximately a quarter of previously undetected infections among pregnant women.
(A) 调查苏格兰育龄妇女丙型肝炎病毒(HCV)感染的患病率及人口统计学特征;(B) 确定出生前被诊断出的母亲HCV感染程度。
(A) 2000年3月至10月在苏格兰各地收集的常规新生儿筛查剩余干血斑样本,去除标识符后进行匿名HCV抗体检测;(B) 对苏格兰出生数据库和确诊HCV感染数据库进行电子记录链接。
(A) 在30259份样本中,121份酶联免疫吸附试验呈重复反应性,其中88份在重组免疫印迹试验中被确认为抗HCV阳性,血清阳性率为0.29 - 0.40%。25 - 29岁人群(0.4 - 0.57%)、高贫困地区(0.92 - 1.07%)、大格拉斯哥地区(0.83 - 0.96%)和格兰扁地区(0.38 - 0.62%)的HCV血清阳性率较高。格拉斯哥高贫困地区居民的HCV感染调整后相对风险最高(7.2(95%置信区间2.0 - 25.5))。(B) 在分娩时发现的121例女性HCV感染中,估计分别有24%和46%在怀孕前和出生前被诊断出。
苏格兰育龄妇女中的HCV患病率与注射吸毒人群的预期患病率一致。根据报告的母婴传播率,预计每年有8 - 11例儿童感染。仅24%的感染妇女在怀孕前被诊断出,这表明HCV在注射吸毒人群中未被识别的程度。目前的HCV筛查方法——仅对有注射吸毒史(或其他感染风险因素)的人进行检测——能识别出约四分之一此前未被发现的孕妇感染病例。